Literature DB >> 14615889

Human T lymphotropic virus type 1 in a seronegative B chronic lymphocytic leukemia patient.

Pinhas Stark1, Walter Bodemer, Horst Hannig, Jacob Luboshitz, Matityahu Shaklai, Batya Shohat.   

Abstract

Human T lymphotropic virus type 1 (HTLV-1) is the etiological agent of adult T cell leukemia and HTLV-1-associated myelopathy/tropical spastic paraparesis. HTLV-1 infection in patients with B cell-type chronic lymphocytic leukemia (B-CLL) is rare and has been reported only in areas in which HTLV-1 is endemic. In the present study, we detected HTLV-1 proviral DNA by polymerase chain reaction, using tax primers, in peripheral blood lymphocytes from a B-CLL patient, an immigrant to Israel, where HTLV-1 infection is not endemic. F344 rats injected intravenously with peripheral blood lymphocytes obtained from the patient developed HTLV-1 antibodies. Titers of antibody to HTLV-1 in the rat blood were 1:512 by particle agglutination; enzyme-linked immunosorbent assay and Western blotting were also positive. No antibody against HTLV-1 was demonstrated in the animal model after inoculation of either purified B lymphocytes from the B-CLL patient or peripheral blood mononuclear cells from healthy donors. This is one of the few studies showing the presence of HTLV-1 provirus in T lymphocytes of a B-CLL patient who had multiple infections, and died of salmonella sepsis, and the first report of HTLV-1 antibody induction in an animal model by inoculation of lymphocytes obtained from an HTLV-1-infected B-CLL patient.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14615889     DOI: 10.1007/s00430-002-0169-3

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN: 0300-8584            Impact factor:   3.402


  37 in total

1.  Nontyphoid Salmonella bacteremia: age-related differences in clinical presentation, bacteriology, and outcome.

Authors:  Z Shimoni; S Pitlik; L Leibovici; Z Samra; H Konigsberger; M Drucker; V Agmon; S Ashkenazi; M Weinberger
Journal:  Clin Infect Dis       Date:  1999-04       Impact factor: 9.079

2.  Molecular and immunologic analysis of a chronic lymphocytic leukemia case with antibodies against human T-cell leukemia virus.

Authors:  J W Clark; B H Hahn; D L Mann; F Wong-Staal; M Popovic; E Richardson; D M Strong; W S Lofters; W A Blattner; W N Gibbs
Journal:  Cancer       Date:  1985-08-01       Impact factor: 6.860

3.  Lymphokine production by cultured human T cells transformed by human T-cell leukemia-lymphoma virus-I.

Authors:  S Z Salahuddin; P D Markham; S G Lindner; J Gootenberg; M Popovic; H Hemmi; P S Sarin; R C Gallo
Journal:  Science       Date:  1984-02-17       Impact factor: 47.728

4.  Unique cell lines harbouring both Epstein-Barr virus and adult T-cell leukaemia virus, established from leukaemia patients.

Authors:  N Yamamoto; T Matsumoto; Y Koyanagi; Y Tanaka; Y Hinuma
Journal:  Nature       Date:  1982-09-23       Impact factor: 49.962

5.  HTLV-I--associated B-cell CLL: indirect role for retrovirus in leukemogenesis.

Authors:  D L Mann; P DeSantis; G Mark; A Pfeifer; M Newman; N Gibbs; M Popovic; M G Sarngadharan; R C Gallo; J Clark
Journal:  Science       Date:  1987-05-29       Impact factor: 47.728

Review 6.  An HTLV-I vaccine: why, how, for whom?

Authors:  G de Thé; R Bomford
Journal:  AIDS Res Hum Retroviruses       Date:  1993-05       Impact factor: 2.205

Review 7.  Chronic progressive myeloneuropathy in WKAH rats induced by HTLV-I infection as an animal model for HAM/TSP in humans.

Authors:  T Yoshiki
Journal:  Intervirology       Date:  1995       Impact factor: 1.763

8.  Characterization of a novel HTLV-infected cell line.

Authors:  H P Koeffler; I S Chen; D W Golde
Journal:  Blood       Date:  1984-08       Impact factor: 22.113

9.  A survey of human leukaemias for sequences of a human retrovirus.

Authors:  F Wong-Staal; B Hahn; V Manzari; S Colombini; G Franchini; E P Gelmann; R C Gallo
Journal:  Nature       Date:  1983-04-14       Impact factor: 49.962

10.  Serological and molecular survey for HTLV-I infection in a high-risk Middle Eastern group.

Authors:  D Meytes; B Schochat; H Lee; G Nadel; Y Sidi; M Cerney; P Swanson; M Shaklai; Y Kilim; M Elgat
Journal:  Lancet       Date:  1990 Dec 22-29       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.